Union Health Ministry Bans 16 Fixed Dose Combinations Over Efficacy Concerns

Following a Supreme Court mandate for a comprehensive review, the Union Ministry of Health and Family Welfare has prohibited the manufacture, sale, and distribution of 16 Fixed Dose Combinations (FDCs) of drugs. The decision follows reports from an Expert Committee constituted by the Drugs Technical Advisory Board (DTAB), which concluded that these specific combinations offer no therapeutic benefit and may pose risks to human health. The notification, issued under Section 26A of the Drugs and Cosmetics Act of 1940, took immediate effect.

The banned list includes various antibiotics, antispasmodics, dermatological treatments, and diabetes-related combinations. Experts emphasized that the decision is rooted in the principle that every component in a drug combination must serve a clear scientific purpose. Medical practitioners noted that the combinations often lacked evidence of superior efficacy compared to individual medicines and potentially exposed patients to unnecessary drug interactions, side effects, and higher financial burdens. For instance, the combination of Gliclazide and Chromium Picolinate was noted to be inconsistent with international clinical guidelines.

Health professionals are urging patients currently taking these medications not to stop their treatment abruptly. Instead, they recommend consulting with their treating physicians to identify safe, evidence-based alternatives. This regulatory move is viewed as a significant step toward rational prescribing practices in India, with officials reinforcing that the goal is not to discredit individual molecules but to ensure that only scientifically validated formulations are accessible to the public.